Dang, Chau T.

Publications

Sort by

Co-Author Network

selected publications

Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer. JAMA cardiology. 2020 Academic Article GET IT
Times cited: 31
Effects of Exercise Therapy Dosing Schedule on Impaired Cardiorespiratory Fitness in Patients With Primary Breast Cancer: A Randomized Controlled Trial. Circulation. 2020 Academic Article GET IT
Times cited: 20
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 178
The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Academic Article GET IT
Times cited: 12
Assessment of Early Radiation-Induced Changes in Left Ventricular Function by Myocardial Strain Imaging After Breast Radiation Therapy. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography. 2019 Academic Article GET IT
Times cited: 26
Efficacy of Exercise Therapy on Cardiorespiratory Fitness in Patients With Cancer: A Systematic Review and Meta-Analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Review GET IT
Times cited: 154
Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: A randomized controlled trial. Cancer. 2018 Academic Article GET IT
Times cited: 58
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer. Clinical breast cancer. 2018 Academic Article GET IT
Times cited: 29
Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience. The oncologist. 2017 Academic Article GET IT
Times cited: 24
Exercise and Prognosis on the Basis of Clinicopathologic and Molecular Features in Early-Stage Breast Cancer: The LACE and Pathways Studies. Cancer research. 2016 Academic Article GET IT
Times cited: 35
Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study. Breast cancer research and treatment. 2016 Academic Article GET IT
Times cited: 28
Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer. The oncologist. 2016 Academic Article GET IT
Times cited: 38
Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016 Academic Article GET IT
Times cited: 47
Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Review GET IT
Times cited: 75
Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA oncology. 2016 Academic Article GET IT
Times cited: 54
Breast Cancer Risk in Childhood Cancer Survivors Without a History of Chest Radiotherapy: A Report From the Childhood Cancer Survivor Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 62
A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. Clinical breast cancer. 2015 Academic Article GET IT
Times cited: 1
Effect of Unblinding on Participants' Perceptions of Risk and Confidence in a Large Double-Blind Clinical Trial of Chemotherapy for Breast Cancer. JAMA oncology. 2015 Academic Article GET IT
Times cited: 4
Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast cancer research and treatment. 2015 Academic Article GET IT
Times cited: 52
Do MRI and mammography reliably identify candidates for breast conservation after neoadjuvant chemotherapy?. Annals of surgical oncology. 2015 Academic Article GET IT
Times cited: 24
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 527
The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy. Annals of surgical oncology. 2015 Academic Article GET IT
Times cited: 31
Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 66
The development of dose-dense adjuvant chemotherapy. The breast journal. 2014 Review GET IT
Times cited: 11
Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103. Breast cancer research and treatment. 2014 Academic Article GET IT
Times cited: 36
Sentinel node biopsy after neoadjuvant chemotherapy: a new standard for patients with axillary metastases?. JAMA. 2013 Editorial Article GET IT
Times cited: 12
Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. Cancer. 2013 Academic Article GET IT
Times cited: 16
Epoetin alfa: to give or not to give. Journal of the National Cancer Institute. 2013 Editorial Article GET IT
Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer. Cancer prevention research (Philadelphia, Pa.). 2013 Academic Article GET IT
Times cited: 58
Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. Breast cancer research and treatment. 2012 Review GET IT
Times cited: 28
Epirubicin: is it like doxorubicin in breast cancer? A clinical review. Breast (Edinburgh, Scotland). 2012 Review GET IT
Times cited: 124
The end of an era: shall we move forward?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Editorial Article GET IT
Times cited: 3
Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clinical breast cancer. 2011 Academic Article GET IT
Times cited: 109
A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Academic Article GET IT
Times cited: 49
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 126
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 25
Anthracyclines are a critical component of adjuvant chemotherapy regimens for high-risk early breast cancer. Oncology (Williston Park, N.Y.). 2011 Comment GET IT
Times cited: 1
Adjuvant taxanes: more to the story. Clinical breast cancer. 2010 Review GET IT
Times cited: 11
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 42
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 25
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 42
Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible. Clinical breast cancer. 2008 Academic Article GET IT
Times cited: 11
Dose-dense chemotherapy with trastuzumab is an appropriate option. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Letter GET IT
Times cited: 1
The taxane limbo: how low can we go?. Journal of the National Cancer Institute. 2008 Editorial Article GET IT
Times cited: 4
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 51
Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer. Breast cancer research and treatment. 2007 Academic Article GET IT
Times cited: 27
Current status of the taxanes as adjuvant therapy for breast cancer. Breast (Edinburgh, Scotland). 2007 Review GET IT
Times cited: 3
Cardiac dysfunction associated with trastuzumab. Expert opinion on drug safety. 2006 Review GET IT
Times cited: 39
A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy. Journal of the American Geriatrics Society. 2006 Academic Article GET IT
Times cited: 78
Can granulocyte-colony stimulating factor worsen anemia?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Editorial Article GET IT
Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. Journal of the American Geriatrics Society. 2006 Academic Article GET IT
Times cited: 210
Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg. Clinical breast cancer. 2006 Review GET IT
Times cited: 18
Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. Breast cancer research and treatment. 2006 Academic Article GET IT
Times cited: 82
Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions. Expert review of anticancer therapy. 2006 Review GET IT
Times cited: 10
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 29
The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer. 2004 Academic Article GET IT
Times cited: 145
Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 58
Adjuvant therapy for breast cancer: practical lessons from the early breast cancer trialists' collaborative group. Breast disease. 2004 Review GET IT
Times cited: 4
Risk models for neutropenia in patients with breast cancer. Oncology (Williston Park, N.Y.). 2003 Review GET IT
Times cited: 3
Dose-dense treatment prolongs disease-free survival of women with node positive breast cancer. Cancer treatment reviews. 2003 Academic Article GET IT
Potential role of selective COX-2 inhibitors in cancer management. Oncology (Williston Park, N.Y.). 2002 Review GET IT
Times cited: 44
Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. The Lancet. Oncology. 2001 Review GET IT
Times cited: 496
Enhanced endothelial cell apoptosis in splenic tissues of patients with thrombotic thrombocytopenic purpura. Blood. 1999 Academic Article GET IT
Times cited: 66
Pathologic distinctions among the thrombotic microangiopathies. Clinical nephrology. 1998 Letter GET IT
Times cited: 1
Aseptic meningitis secondary to carbamazepine therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 1996 Review GET IT
Times cited: 13

more ...

less ...

Background

education and training

M.D., University of South Carolina Medical School 1992
B.S., Clemson University 1988

Contact

full name

Chau T. Dang

VIVO Weill Cornell Medical College

Chau T. Dang Professor of Clinical Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name